Phase 3
Completed N=750
Disease Management for Smoking Cessation
Source: ClinicalTrials.gov NCT00440115 ↗Enrolled (actual)
750
Serious AEs
2.5%
Results posted
Jun 2017
Primary outcomePrimary: 7-day Point Prevalence Abstinence From Cigarettes — 68; 56; 56 Participants — p=0.54
◆ Published Evidence
Established
77citations · ~5 / year
Effect of varying levels of disease management on smoking cessation: a randomized trial.
Summary
The primary aim of this study is to assess the effectiveness of both high and low intensity, disease management programs for smoking. The hypotheses are to compare abstinence from cigarettes, the number of quit attempts, and smokers motivation at 24 months between participants receiving high and low intensity disease management and those receiving usual care.
Linked Publications (5)
-
Effect of varying levels of disease management on smoking cessation: a randomized trial.
-
Design and baseline characteristics from the KAN-QUIT disease management intervention for rural smokers in primary care.
-
Predictors of early versus late smoking abstinence within a 24-month disease management program.
-
The impact of repeated cycles of pharmacotherapy on smoking cessation: a longitudinal cohort study.
-
Correlates of self-efficacy among rural smokers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY 7-day Point Prevalence Abstinence From Cigarettes |
68; 56; 56 | 0.54 |
| SECONDARY Number of Quit Attempts |
171; 160; 142; 2; 4; 3 | — |
| SECONDARY Progress in Stage of Change |
24; 25; 15; 65; 74; 89 | — |
Eligibility Criteria
Inclusion Criteria
- Over the age of 18
- Reported smoking at least 10 cigarettes per day for at least 25 of the last 30 days
- Speak English
- Their regular physician is a participating physician
- Working home telephone or cellular phone
Exclusion Criteria
- Women who are pregnant or planning to become pregnant in the next two years
- Plan on moving within two years
- Display signs of dementia or other mental disorders
- Live with a smoker already enrolled
Data sourced from ClinicalTrials.gov (NCT00440115) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.